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permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.SUMMARYAdipose-derived stem/stromal cells (ASCs) from the anatomically distinct subcutaneous and visceral depots of white adipose tissue (WAT)
differ in their inherent properties. However, little is known about the molecular identity and definitive markers of ASCs from these
depots. In this study, ASCs from subcutaneous fat (SC-ASCs) and visceral fat (VS-ASCs) of omental region were isolated and studied.
High-content image screening of over 240 cell-surface markers identified several potential depot-specific markers of ASCs. Subsequent
studies revealed consistent predominant expression of CD10 in SC-ASCs and CD200 in VS-ASCs across 12 human subjects and in
mice. CD10-high-expressing cells sorted from SC-ASCs differentiated better than their CD10-low-expressing counterparts, whereas
CD200-low VS-ASCs differentiated better than CD200-high VS-ASCs. The expression of CD10 and CD200 is thus depot-dependent
and associates with adipogenic capacities. These markers will offer a valuable tool for tracking and screening of depot-specific stem
cell populations.INTRODUCTION
White adipose tissue (WAT) has been increasingly appreci-
ated as an alternative source of mesenchymal stem cells
(MSCs) traditionally isolated from the bonemarrow. Subcu-
taneous WAT can be isolated by minimally invasive
liposuction procedure. Additionally, adipose-derived stem/
stromal cells (ASCs) are relatively abundant in the WAT
where as much as 1% of human adipose cells are ASCs as
compared to only 0.001%–0.002% MSCs in the bone
marrow (Fraser et al., 2006). The differentiation capacity,
immunobiological properties, and secretome of ASCs offer
tremendous therapeutic potential in regenerative medicine
(Ong and Sugii, 2013).
By the convention of the International Society for
Cellular Therapy (ISCT), MSCs from various sources,
including ASC, are defined as being (1) plastic-adherent
in the standard cell-culture condition; (2) multipotent,
i.e., able to differentiate into osteoblasts, adipocytes, and
chondrocytes in vitro; and (3) positive for CD73, CD90,
and CD105 and negative for CD11b or CD14, CD19 or
CD79a, CD34, CD45, and HLA-DR in their cell-surface
immunophenotype (Dominici et al., 2006). In addition,
the recent revised statement of ISCT and InternationalStem CellFederation for Adipose Therapeutics and Science (IFATS)
suggests additional markers for ASCs, which are positive
for CD36 and negative for CD106, compared to bone-
marrow MSCs (Bourin et al., 2013). Thus, it is beginning
to be recognized that MSCs from different origins may
have different cell-surface marker expression, but few
studies have analyzed their expression differences in a
comprehensive manner.
Increasing evidence suggests that ASCs derived from
WAT of different depot origins are distinct populations of
cells that differ in their inherent properties (Macotela
et al., 2012; Tchkonia et al., 2005, 2006). A notable func-
tional difference is that subcutaneous fat ASCs (SC-ASCs)
proliferate at a higher rate and differentiate better than
visceral fat ASCs (VS-ASCs) in response to in vitro adipo-
genic stimuli (Macotela et al., 2012; Tchkonia et al.,
2005). The functional difference of SC- and VS-ASCs
together with regional variation in cellular interaction, cir-
culation, innervations, and anatomic constraints in the SC
and VS depots ofWATare thought to be the underlying fac-
tors contributing to pathophysiological variation of these
two WAT depots in relation to metabolic homeostasis
(Tchkonia et al., 2007, 2013). The SC depot physiologically
stores excess lipids thus preventing their deposition intoReports j Vol. 2 j 171–179 j February 11, 2014 j ª2014 The Authors 171
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other hand, leads to pathological metabolic profile because
of dysfunction in lipid storage (Despre´s and Lemieux,
2006). Differences in these properties are at least partly
cell autonomous and recapitulated in vitro in ASCs isolated
from these depots (Tchkonia et al., 2013).
Further characterization of SC-ASCs and VS-ASCs is
necessary to understand their pathophysiological roles in
metabolism and therapeutic relevance in regenerative
medicine. However, the definitive markers and molecular
identity of ASCs from the two fat depots remain obscure
to date. This limitation would hamper our future efforts
from tracking and screening for distinct populations of
stem cells that are destined to become different fat depots.
This study aims to address this fundamental question
about ASCs from SC and VS depots of WAT by identifying
depot-specific ASC cell-surface markers.RESULTS
High-Content Screening of Cell-Surface Markers
Identifies Potential Subcutaneous-Specific CD10 and
Visceral-Specific CD200 ASC Markers
In order to study molecular-marker differences of stem cell
populations of different depots, stromal vascular fractions
(SVF) of SC and VS fat depots were isolated and ASCs were
enriched by serial passage culture of SVF. These ASCs were
confirmed for their multipotency by osteogenesis and
chondrogenesis assays (Figure S1A available online). SC-
ASCs andVS-ASCswere subjected to invitro standardadipo-
genic differentiation cocktail (insulin, dexamethasone, and
isobutylmethylxanthine [IBMX]). As previously reported
(Macotela et al., 2012; Tchkonia et al., 2005), SC-ASCs un-
derwent robust adipogenesis whereas VS-ASCs were rela-
tively resistant to the adipogenic stimuli as revealed by Oil
Red O staining (Figure S1B). This trend of adipogenic-sensi-
tive SC-ASCs and adipogenic-resistant VS-ASCs persisted at
all the time points even when the standard adipogenesis
cocktail was augmented with indomethacin, a strong
inducer of adipogenesis by potently activating PPARg, a
master regulator of adipogenesis. We hypothesized thatFigure 1. High-Content Screening of ASCs for Potential Depot-Sp
(A) Strategy for screening and identification of cell-surface markers.
(B) Representative fluorescence images of S1-derived SC-ASC and VS-A
CD105). BM-MSC and HFF-1 were intended as controls.
(C) Representative fluorescence images that suggested depot-specifi
source) and that of CD142 and CD200 in VS-ASCs (S1). The cells were fir
Surface Marker Screening Panel and then with Alexa-Fluor-647-conju
counterstained with Hoechst 33342 (blue). The scale bar represents 20
one positive signal from the Lyoplate screening can be obtained upo
See also Figure S1.
Stem Cellintrinsic differences in their molecular properties leading
to thephenotypic variationof SC-ASCs andVS-ASCs should
be reflected by differences in the expression of their cell-sur-
face markers.
We took an approach consisting of three stages to iden-
tify depot-specific ASC markers (Figure 1A). First, a high-
content screening assay of 242 human cell-surface markers
was performed on five cell lines: cultured SC-ASC from sub-
ject 1 (S1), VS-ASCs from S1 and commercially obtained
SC-ASC, together with bone marrow (BM)-derived MSC
and human foreskin fibroblast (HFF-1) as controls. This
was followed by the second stage where additional experi-
ments including immunostaining assays were performed
for further verification of selected candidate markers in
the cell lines used in the first stage plus additional ones
derived from two other subjects. At the final stage, a total
of 12 human subjects, along with normal lean and obese
mice, were investigated for determination of specific
markers by experimental analyses such as flow cytometry
and quantitative polymerase chain reaction (qPCR).
Details of selection criteria and markers selected as well as
statistical consideration are summarized in Supplemental
Information and Tables S3 and S4.
As expected, both SC- and VS-ASCs of S1 as well as
BM-MSC were positively immunostained with the con-
ventional MSC markers, CD73, CD90, and CD105, in the
high-content image screening (Figure 1B). However, the
negative control HFF-1 was also stained positively to
some extent, especially for CD90, illustrating some limita-
tions of existing markers. Based on the fluorescence inten-
sity analyzed using image analysis software and visual
confirmation, cell-surface-marker candidates that showed
differential immunofluorescence signals between SC- and
VS-ASCs in the high-content screening were selected for
further studies. Fluorescence analyses of all the markers
with at least one positive signal are described in Tables S3
and S4. Examples of these included CD10 and CD141 as
potential SC-ASC markers, whereas CD142 and CD200
were selected as potential VS-ASC markers (Figure 1C).
Follow-up immunofluorescence studies were performed
independently to study the expression of selected cell-sur-
face-marker candidates across S1–S3 as well as commercialecific Cell-Surface Markers
SC immunostained with conventional MSC markers (CD73, CD90, and
c expression of CD10 and CD141 in SC-ASCs (S1 and commercial
st stained with primary antibodies from the BD Lyoplate Human Cell
gated secondary antibody (red). The nuclei of all viable cells were
0 mm. The fluorescence raw images for all other markers with at least
n request.
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Figure 2. mRNA and Protein Expression
Profiles of CD10 and CD200 in SC- and
VS-ASCs across Subjects
(A) qPCR data that show the relative
expression level of CD10 and CD200 between
SC-ASCs (expression level normalized as 1)
and VS-ASCs across S1–S6. The value of each
subject is the mean from three technical
replicates from a qPCR reaction. Statistical
significance was assessed across the six
independent subjects by using Wilcoxon
signed-rank test.
(B) Western blot analysis that shows the
protein expression of CD10 between SC-
ASCs and VS-ASCs across S1–S3 and in
commercial SC-ASCs. The protein expression
of CD200 was not shown due to unavail-
ability of antibody with satisfactory quality
for western blotting.
See also Figure S2.
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CD10 in SC-ASCs and CD200 in VS-ASCs were consistent
across S1–S3 (Figure S2). On the other hand, CD141, for
example, was found to be predominantly expressed in
SC-ASCs in S1, but not in S2 or S3. Similarly, CD142 was
predominantly expressed in VS-ASCs in S1 and S2, but
not in S3 (Figure S2). Variations were also found in other
cell-surface markers, consistent with the recent report of
heterogeneities in surface-marker expression among indi-
vidual SC-ASCs (Baer et al., 2013). Therefore, we excluded
heterogeneous markers such as CD141 and CD142 and
selected CD10 and CD200 for further studies.
mRNA and Protein Expression of CD10 and CD200
Real-time qPCR showed that the mRNA expression of
CD10 was consistently higher in the SC-ASCs relative to
VS-ASCs, whereas CD200 was consistently lower in the
SC-ASCs relative to VS-ASCs across S1–S6 (Figure 2A).
This was complemented by protein expression analysis us-
ing western blotting of CD10 (Figure 2B).
In order to examine whether these potential depot-spe-
cific markers were valid in another species, we investigated
expression of Cd10 and Cd200 in mouse. C57BL6/J mice
were either fed normal chow (NC) or high fat diet (HFD)
to induce obesity. The body weight was 39.9 ± 0.83 g for
NC and 60.0 ± 0.95 g for HFD mice (n = 5). As epididymal
andmesenteric fat depots, instead of omental fat, aremajor
visceral fat found in mice, we isolated visceral ASCs from
epididymal and mesenteric fat depots and subcutaneous
ASCs from inguinal fat depot in these animals. The qPCR
analysis indicated that Cd10 was predominantly expressed
in ASCs from subcutaneous fat, whereas Cd200 was highly
expressed in ASCs from visceral (epididymal and mesen-174 Stem Cell Reports j Vol. 2 j 171–179 j February 11, 2014 j ª2014 The Ateric) fat in both NC- and HFD-fed mice (Figure S3A). This
result suggests that the depot-dependant expression
pattern of CD10 and CD200 holds true in mouse species
and that the diet intervention does not affect this differen-
tial expression pattern between depots.
Flow cytometry analysis was performed to study the
subpopulation composition of the cultured ASCs. As con-
trol, both the SC- and VS-ASCs of all subjects expressed the
conventional MSC markers by this analysis (Figure 3A).
Flow cytometry showed significantly predominant expres-
sion of CD10 by SC-ASCs (CD10+ SC-ASCs: mean 50.6%
[range of 17.9%–83.5% across S1 to S12] versus CD10+
VS-ASCs: mean 1.0% [0.1%–5.4%]; Figures 3B and 3D).
Similarly, significantly higher expression of CD200 by
VS-ASCs (CD200+ SC-ASCs: mean 24.0% [0.9%–56.3%]
versus CD200+ VS-ASCs: mean 80.0% [43.3%–98.5%])
was observed (Figures 3C and 3E). These results further es-
tablished CD10 as a SC-ASC-specific marker and CD200 as
a VS-ASC-enriched marker. Similar differential expression
patterns were also observed for SVF (passage 0), which is
less processed and composed of heterogeneous cell popu-
lations (Figure S3B). It was previously reported that prop-
erties of MSCs can be affected by differences in culture
condition such as serum and glucose concentrations
(Sotiropoulou et al., 2006). We addressed whether
different fetal bovine serum (FBS) and glucose concentra-
tions have any effects on expression of CD10 and
CD200. As is shown in Figure S3C, glucose concentration
did not affect CD10 and CD200 expression of SC-ASCs and
VS-ASCs, though only CD10+ SC-ASCs seemed to moder-
ately increase in medium with 10% FBS compared to
15% FBS. In any case, depot specificity was preserved
regardless of FBS or glucose.uthors
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Adipogenesis
As described above, SC-ASCs differentiate better into
mature adipocytes than VS-ASCs by the standard in vitro
adipogenesis protocol. In order to investigate the expres-
sion changes of CD10 and CD200 during adipogenesis,
qPCR was performed in differentiating SC-ASCs and
VS-ASCs. The mRNA expression level of CD10 increased
after adipogenic stimuli, and this increase positively
correlated with those of adipogenic markers, PPARG and
aP2 (Figures 4A and S4A). In contrast, the CD200 level
decreased after adipogenesis was initiated and exhibited
a negative correlation with adipogenic markers (Figure 4A
and S4A). Increase of CD10 during adipogenesis of SC-
ASCs was also confirmed at the protein level by western
blot (Figure 4B).Adipogenic Potential of ASC Subpopulations
Expressing High or Low Level of CD10 or CD200
The results above led us to postulate that SC-ASC-specific
CD10 may mark cell populations with higher adipogenic
capacities, whereas VS-ASC-selective CD200 may mark
those with less adipogenic capacities, which are consistent
with intrinsic properties of respective ASCs. In order to test
our hypothesis, we sorted SC-ASCs into two populations:
CD10-high-expressing (CD10hi) and CD10-low-expressing
(CD10lo) cells (Figure S4B). Similarly, VS-ASCs were sorted
into CD200-high-expressing (CD200hi) and CD200-low-
expressing (CD200lo) cells (Figure S4C). These populations
were subjected to the standard in vitro adipogenic induc-
tion. The result indicated that CD10hi cells sorted from
SC-ASCs differentiate significantly better than their
CD10lo counterparts as revealed by Oil Red O staining
and absorbance reading of its extracted solvents (Fig-
ure 4C). Conversely, CD200lo cells sorted from VS-ASCs
were found to differentiate significantly better than the
CD200hi counterparts (Figure 4D). These data suggest
that CD10 is a prospective marker for high adipogenic
potential, whereas CD200 is a predictive marker for low
adipogenic capacity.DISCUSSION
Wehave demonstrated herein that CD10 and CD200 show
consistent differential expression profiles between SC- and
VS-ASCs. The expression levels of these markers correlate
with adipogenic capacities, i.e., positive correlation of
CD10 and negative correlation of CD200 with adipogenic
potential. Thus, CD10 and CD200 may be used as prospec-
tive markers. Despite importance of cell-surface markers to
identify and track stem cells including MSCs and ASCs and
known pathophysiological differences between subcutane-Stem Cellous and visceral fat depots, few previous studies have
comprehensively examined differences of surface-marker
expression in the depot-specific manner. Identification of
these depot-specific markers will allow us to differentially
isolate, visualize, and characterize ASCs in the depot-spe-
cific manner.
Previous cell-surface-marker analyses were performed
on SC-ASCs, which are easily and routinely obtained by
liposuction procedure. In those studies, flow cytometry
analyses of preselected cell-surface proteins indicate that
SC-ASCs share many cell-surface-marker expressions with
BM-MSCs (Gronthos et al., 2001; Katz et al., 2005). A recent
study using high-throughput screening of cell-surface
markers in SC-ASCs reported significant heterogeneity in
their expression of many markers among five subjects
(Baer et al., 2013). Lack of control samples, however,
made it difficult to assess the degree of variation compared
to other cell types among individuals. Whereas we have
also noted significant heterogeneities in expression of
many cell-surface markers, we found that expression of
CD10 and CD200 in ASCs are clearly distinguished from
that of BM-MSCs, which express these at much lower
levels, and that their depot-specific differences are consis-
tent across human subjects and mice.
CD10 (also known as neprilysin, neutral endopeptidase,
enkephalinase, and common acute lymphoblastic leuke-
mia antigen) is a cell-surface metallopeptidase that in-
activates a number of signaling substrates (Maguer-Satta
et al., 2011). It was previously reported that CD10 is a
cell-surface marker of mammary stem cells and that sort-
ing by CD10 enriches sphere-forming stem/progenitor
populations (Bachelard-Cascales et al., 2010). In fact, a
recent statement defining ASC markers by IFATS and
ISCT listed CD10 as a possible ASC-specific marker relative
to BM-MSC (Bourin et al., 2013). However, these ASCs
were presumably derived from subcutaneous fat depots.
Our study indicates that ASCs from visceral depots would
not express CD10 in contrast to commonly studied ASCs
from subcutaneous depots. CD200, also called OX2, is a
member of the immunoglobulin superfamily of proteins,
whose biological function is unclear but implicated in
multiple immunoregulatory activities of myeloid and
other immune cell types (Gorczynski et al., 2004). One
study noted high CD200 expression in MSCs isolated
fromWharton’s jelly compared to BM-MSCs and (presum-
ably subcutaneous) ASCs (Najar et al., 2012). These au-
thors hypothesized that the inflammatory environment
of Wharton’s jelly contributed to higher MSC expression
of CD200. Visceral fat depot is thought to have similar in-
flammatory conditions (Mathis, 2013) and may result in
abundant expression of CD200. Interestingly, CD200
was identified as a marker to enrich endocrine cell popula-
tions derived from human embryonic stem cells in orderReports j Vol. 2 j 171–179 j February 11, 2014 j ª2014 The Authors 175
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Figure 4. CorrelationofCD10-andCD200-
Expression Levels and Adipogenesis
(A) SC-ASCs differentiated better than their
VS-ASC counterparts into adipocytes in
response to standard adipogenic stimula-
tion. Adipogenesis of ASCs were induced
with the standard adipogenic cocktail plus
indomethacin for D0–D4, followed by
maintenance medium with insulin alone
(D4–D12). The mRNA expression level of
CD10 positively correlated with induction
of adipogenesis as determined by qPCR. On
the other hand, a negative correlation was
observed for CD200 (data represented by
S6). Each value is the mean ± SEM from
two independent experiments. See also
Figure S4A.
(B) Western blot showed increased CD10
protein expression in response to adipo-
genic stimulation. The densitometry of
CD10, measured by ImageJ software, was
normalized against b-actin as a loading
control (represented by commercial SC-
ASCs). a.u., arbitrary units.
(C) CD10hi cells sorted from SC-ASCs differ-
entiated better than their CD10lo counter-
parts. Data are represented by S4, with
similar results obtained in other subjects.
(D) CD200lo cells sorted from VS-ASCs
differentiated better than the CD200hi
counterparts. Data are represented by S2,
with similar results by other cells.
The scale bars represent 200 mm (C and D).
Each value is the mean ± SEM from three independent wells from one cell preparation. Statistical significance was assessed by using
Student’s t test: ***p < 0.001, **p < 0.01, *p < 0.05. See also Figures S4B–S4E.
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2011). This may indicate an endocrine origin of visceral
fat-derived cells. Future studies may be directed at deter-
mining the functional relevance of these molecules in
regulating adipogenesis.EXPERIMENTAL PROCEDURES
Further details of each procedure are found in Supplemental
Information.Figure 3. Flow Cytometry Analysis of SC- and VS-ASC Populations
(A) Both the SC- and VS-ASCs of all subjects expressed the conventio
(B) Histograms showing CD10-expressing cell populations were almo
(C) Histograms showing CD200-expressing cell populations were pred
(D) Line graph showing CD10-expressing cell populations were almos
(E) Line graph showing CD200-expressing cell populations were pred
Histograms: Relative cell count is indicated in y axis, and fluorescenc
axis. Grey line represents ‘‘unstained control,’’ and the percentage of
significance was assessed across the 12 independent subjects by usin
Stem CellIsolation and Culture of ASCs
WAT was isolated from the subcutaneous (abdominal region) and
visceral (omental region) depots from 12 human obese volunteers
(S1–S12) undergoing bariatric surgery (Table S1), with approval by
the Domain Specific Review Board at National Healthcare Group,
Singapore. ASCs were then isolated and cultured, as described pre-
viously (Sugii et al., 2011).
Adipogenesis and Oil Red O Staining
Two days after reaching confluency, cells were induced with
adipogenic cocktail containing 1 mM dexamethasone, 0.5 mMnal MSC markers (represented by S1).
st exclusively found in the SC-ASCs across S1–S12.
ominantly found in the VS-ASCs across S1–S12.
t exclusively found in the SC-ASCs across S1–S12.
ominantly found in the VS-ASCs across S1–S12.
e intensity, FITC (B), or Alexa Fluor 647 (A and C) is indicated in x
positively stained cells is as indicated. For (D) and (E), statistical
g paired Student’s t test. See also Figure S3.
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cells were switched to medium with 167 nM insulin and main-
tained until at least D12. The cells were then fixed and stained
with Oil Red O solution. Stained lipids were extracted by isopropa-
nol and absorbance of extracted solution measured at 500 nm.
High-Content Screening
High-content screening assay of 242 human cell-surface markers
was performed using BD Lyoplate Human Cell Surface Marker
Screening Panel (BD Biosciences) and ImageXpressMicro (Molecu-
lar Devices). Fluorescence intensity was analyzed by MetaXpress
cellular image analysis software and visual confirmation.
Mouse Studies
Thirty-nine-week-old male C57BL6/J mice were fed either with
normal chow or high fat diet for 27 weeks (five mice each).
Inguinal (subcutaneous), epididymal, and mesenteric fat depots
were harvested and ASCs isolated. This animal work was approved
by the Institutional Animal Care and Use Committee of Biological
Resource Centre, Singapore.
Real-Time qPCR
Total RNA was extracted using Trizol reagent (Invitrogen) and
treated with DNase I. cDNA conversion wasmade by the RevertAid
Hminus first strand cDNA synthesis kit (Fermentas). qPCRwas per-
formed using the SYBR Green PCR Master Mix on a StepOnePlus
Real-Time PCR System (Applied Biosystems) using the primer pairs
shown in Table S2. Relative mRNA levels were calculated and
normalized to that of GAPDH/Gapdh.
Immunoblot Analysis
Cell lysates (20 mg) were loaded into 10% SDS-PAGE gels and
blotted by the iBlot Dry Blotting System (Invitrogen). Membranes
were blocked and probed with primary antibodies overnight at
4C, followed by horseradish peroxidase-conjugated secondary
antibodies for 1 hr at room temperature.
Flow Cytometry and Cell Sorting
ASCs (passage number > 2) were tripsinized and suspended in
staining buffer (Dulbecco’s modified Eagle’s medium without
phenol red with 2% FBS) for immunostaining. The cells were incu-
bated for 30 min on ice, either directly with a fluorochrome-
conjugated antibody or with an unconjugated primary antibody
followed by an appropriate secondary antibody conjugated with
fluorochrome. The stained cells were washed and suspended in
sorting buffer (PBS with 0.5%BSA and 2mMEDTA) before analysis
by flow cytometry (LSRII; BD Biosciences). Cells were processed in
a similar manner for sorting by Moflo XDP Cell Sorter (Beckman
Coulter).
Statistical Analysis
Results are presented as means ± SEM. The Student’s t test or
Wilcoxon signed-rank test was used where appropriate to deter-
mine differences in the mean or median between two groups. Sta-
tistical consideration for the three-stage approach is described in
Supplemental Information.178 Stem Cell Reports j Vol. 2 j 171–179 j February 11, 2014 j ª2014 The ASUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, four tables, and Stage Selection Criteria
and Statistical Consideration and can be foundwith this article on-
line at http://dx.doi.org/10.1016/j.stemcr.2014.01.002.ACKNOWLEDGMENTS
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